MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$80,728K
EPS
-$0.99
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-09-30
2025-06-30
Research and development
78,883
-
General and administrative
11,353
-
Total operating expenses
90,236
-
Loss from operations
-90,236
-80,873
Interest expense
1,092
1,172
Loss on extinguishment of loan payable
-1,557
-
Interest and other income, net
11,319
11,540
Net loss
-81,566
-70,505
Net unrealized gain on marketable securities
838
-97
Comprehensive loss
-80,728
-70,602
Basic EPS
-0.99
-0.86
Diluted EPS
-0.99
-0.86
Basic Average Shares
82,008,267
81,721,387
Diluted Average Shares
82,008,267
81,721,387
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$80,728K
Net unrealized gain
on marketable...
$838K
Net loss
-$81,566K
Interest and other
income, net
$11,319K
Loss from operations
-$90,236K
Loss on
extinguishment of loan payable
-$1,557K
Interest expense
$1,092K
Total operating
expenses
$90,236K
Research and development
$78,883K
General and
administrative
$11,353K
Buy us a coffee
Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics, Inc. (AKRO)